Physician profile
Nayan Desai
NPI 1316368236
$412,710.09
in general payments reported to CMS, 2019-2025
38 companies · $164K in 2025
The $164K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,742 · 2020: $6,391 · 2021: $2,055 · 2022: $55K · 2023: $43K · 2024: $140K · 2025: $164K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $192K · Consulting Fee: $73K · Grant: $50K · Travel and Lodging: $23K · Food and Beverage: $8,040 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $192,390.23 |
| Consulting Fee | $73,129.75 |
| Grant | $50,000.00 |
| Travel and Lodging | $23,323.84 |
| Food and Beverage | $8,039.58 |
| Education | $194.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88,200.35 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $80,971.30 | 2022-2025 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $43,329.12 | 2025 | Amvuttra |
| Edwards Lifesciences Corporation | $42,482.55 | 2020-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $39,601.24 | 2019-2025 | Xarelto, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29,328.04 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $20,641.66 | 2020-2024 | Jardiance |
| Bridgebio Pharma, INC. | $20,540.47 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals Lp | $15,584.99 | 2020-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $15,064.44 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $7,744.27 | 2019-2025 | Rotapro, Versacross Access Solution, Avvigo Guidance System |
| Medtronic, INC. | $5,376.86 | 2021-2025 | Corevalve Evolut R, Hawkone, Micra |
| Abiomed | $1,351.25 | 2022-2025 | Impella |
| Abbott Laboratories | $703.29 | 2019-2025 | Diamondback Coronary, Emboshield Nav6, Mini Trek |
| Shockwave Medical, INC | $466.06 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $292.46 | 2019-2025 | Repatha, Repatha |
| Inari Medical, INC. | $174.65 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic Vascular, INC. | $163.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $103.59 | 2019-2023 | |
| United Therapeutics Corporation | $93.80 | 2024-2025 | Tyvaso, Tyvaso |
| Angiodynamics, INC. | $60.45 | 2021-2023 | Alphavac |
| Lemaitre Vascular, INC. | $55.17 | 2019-2025 | Hydro Lemaitre Valvulotome |
| Stryker Corporation | $51.88 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever |
| Merck Sharp & Dohme LLC | $45.73 | 2023-2025 | Verquvo |
| Cardiovascular Systems INC. | $44.97 | 2019-2021 | |
| Terumo Medical Corporation | $29.98 | 2022 | |
| Biotronik INC. | $29.82 | 2022 | |
| W. L. Gore & Associates, INC. | $22.03 | 2025 | Gore Cardioform Asd Occluder |
| Kiniksa Pharmaceuticals International, Plc | $21.10 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $19.82 | 2020 | |
| Biosense Webster, INC. | $18.39 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.47 | 2025 | |
| Cook Medical LLC | $16.85 | 2024 | Icast Covered Stent System, 6mmx22mmx120cm |
| Astellas Pharma US INC | $16.64 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.24 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $11.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.17 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayan Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.